Cohort iC + CRT | Cohort CRT | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
45–55 Gy | 55+ Gy | 45–55 Gy | 55+ Gy | |||||||
N | % | N | % | P | N | % | N | % | P | |
Facility | 0.39 | 0.0031 | ||||||||
Nonacademic | 335 | 56 | 71 | 52 | 672 | 63 | 163 | 72 | ||
Academic | 259 | 43 | 65 | 47 | 390 | 37 | 58 | 26 | ||
NA | 7 | 1 | 1 | 1 | 4 | 0 | 4 | 2 | ||
Age | 1 | 0.0081 | ||||||||
< 65 | 303 | 50 | 69 | 50 | 474 | 44 | 122 | 54 | ||
≥ 65 | 298 | 50 | 68 | 50 | 592 | 56 | 103 | 46 | ||
NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Gender | 0.047 | 1 | ||||||||
Female | 297 | 49 | 81 | 59 | 514 | 48 | 109 | 48 | ||
Male | 304 | 51 | 56 | 41 | 552 | 52 | 116 | 52 | ||
NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Race | 0.88 | 0.18 | ||||||||
White | 493 | 82 | 115 | 84 | 869 | 82 | 190 | 84 | ||
Black | 81 | 13 | 17 | 12 | 168 | 16 | 27 | 12 | ||
Other | 19 | 3 | 3 | 2 | 20 | 2 | 7 | 3 | ||
NA | 8 | 1 | 2 | 1 | 9 | 1 | 1 | 0 | ||
Insurance | 0.31 | 0.095 | ||||||||
None | 12 | 2 | 2 | 1 | 28 | 3 | 7 | 3 | ||
Nonprivate | 320 | 53 | 63 | 46 | 633 | 59 | 117 | 52 | ||
Private | 265 | 44 | 70 | 51 | 391 | 37 | 99 | 44 | ||
NA | 4 | 1 | 2 | 1 | 14 | 1 | 2 | 1 | ||
Income | 1 | 0.45 | ||||||||
Above median | 389 | 65 | 90 | 66 | 546 | 51 | 118 | 52 | ||
Below median | 207 | 34 | 47 | 34 | 503 | 47 | 97 | 43 | ||
NA | 5 | 1 | 0 | 0 | 17 | 2 | 10 | 4 | ||
Residential setting | 0.33 | 0.077 | ||||||||
Metro | 488 | 81 | 114 | 83 | 807 | 76 | 151 | 67 | ||
Urban | 77 | 13 | 16 | 12 | 189 | 18 | 53 | 24 | ||
Rural | 10 | 2 | 5 | 4 | 34 | 3 | 7 | 3 | ||
NA | 26 | 4 | 2 | 1 | 36 | 3 | 14 | 6 | ||
Charlson-Deyo Score | 1 | 0.25 | ||||||||
0–1 | 575 | 96 | 131 | 96 | 1006 | 94 | 217 | 96 | ||
≥ 2 | 26 | 4 | 6 | 4 | 60 | 6 | 8 | 4 | ||
NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Year of diagnosis | 0.016 | < 0.001 | ||||||||
2004–2007 | 52 | 9 | 7 | 5 | 317 | 30 | 92 | 41 | ||
2008–2011 | 245 | 41 | 74 | 54 | 529 | 50 | 105 | 47 | ||
2012–2015 | 304 | 51 | 56 | 41 | 220 | 21 | 28 | 12 | ||
NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Primary tumor site | 0.068 | 0.014 | ||||||||
Head | 411 | 68 | 94 | 69 | 764 | 72 | 140 | 62 | ||
Body | 171 | 28 | 43 | 31 | 271 | 25 | 74 | 33 | ||
Tail | 19 | 3 | 0 | 0 | 31 | 3 | 11 | 5 | ||
NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Tumor size (cm) | 0.70 | 0.018 | ||||||||
< 3.8 | 265 | 44 | 65 | 47 | 486 | 46 | 82 | 36 | ||
≥ 3.8 | 283 | 47 | 64 | 47 | 448 | 42 | 111 | 49 | ||
NA | 53 | 9 | 8 | 6 | 132 | 12 | 32 | 14 | ||
Clinical N stage | 0.44 | 0.70 | ||||||||
0 | 367 | 61 | 89 | 65 | 692 | 65 | 143 | 64 | ||
1 | 234 | 39 | 48 | 35 | 374 | 35 | 82 | 36 | ||
NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Chemotherapy | 0.20 | 0.74 | ||||||||
Single agent | 166 | 28 | 30 | 22 | 789 | 74 | 164 | 73 | ||
Multi agent | 435 | 72 | 107 | 78 | 277 | 26 | 61 | 27 | ||
NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Total radiation dose (Gy) | < 0.001 | < 0.001 | ||||||||
Median | 50.4 | 59.4 | 50.4 | 59.4 | ||||||
IQR | 50.4–52.5 | 56.0–59.4 | 50.4–52.0 | 57.5–60.0 | ||||||
Fraction | < 0.001 | < 0.001 | ||||||||
Median | 28 | 30 | 28 | 32 | ||||||
IQR | 27–28 | 28–33 | 26–28 | 30–33 |